<DOC>
	<DOCNO>NCT00517556</DOCNO>
	<brief_summary>The primary hypothesis continuous administration OCP ( CCOCP regimen ) result pain relief traditional 21/7 administration primary dysmenorrhea ( PD ) patient .</brief_summary>
	<brief_title>Continuous Administration Oral Contraceptive , Primary Dysmenorrhea</brief_title>
	<detailed_description>It well establish excess prostaglandin production primary dysmenorrhea ( PD ) lead ischemia uterine muscle , consequently cause pelvic pain . A large number drug study pain relief dysmenorrhea patient non-steroid anti-inflammatory drug ( NSAIDs ) effective overall success rate 75 % . Oral contraceptive pill ( OCP ) also establish treatment PD success rate 70 % . Lately , OCP 's use continuously patient endometriosis good pain control traditional administration OCP .</detailed_description>
	<mesh_term>Dysmenorrhea</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Gestodene</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Healthy woman age 1835 history PD ( onset &lt; 3 year menarche ) . Subjects must regular ( 2531 day ) menstrual cycle three month period precede enrollment , symptom moderate severe PD cycle . Patients contraindication OCP therapy . Known suspected secondary dysmenorrhea ( major abdominal pelvic surgery , endometriosis , pelvic inflammatory disease ( PID ) , ovarian cyst , pathological vaginal secretion , chronic abdominal pain , inflammatory bowel disease , irritable bowel syndrome ) . Concomitant treatment oral contraceptive , GnRH agonists antagonist , antiandrogens , gonadotropin , antiobesity drug . The use contraceptive implant , injectable contraceptive intrauterine device . The washout period medication 3 month . Migraines , depression require hospitalization associate suicidal ideation previous estrogen ocp use . Known suspected hypersensitivity trial drug . Patients enrol simultaneously investigative study require med .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Dysmenorrhea</keyword>
	<keyword>continuous OCP</keyword>
</DOC>